Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SpePharm enters into royalty agreement with Paul Capital

Executive Summary

Cancer and critical care company SpePharm Holdings BV has signed a €10mm ($14.75mm) revenue interest acquisition financing with Paul Capital Healthcare to fund SpePharm's recent purchase of European rights to Procter & Gamble's hyperthermia treatment Dantrium. Paul Capital also participated in a simultaneously announced €16mm equity financing for SpePharm, along with other investors.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies